Advertisement

Specialty News

May 11, 2017
May 11, 2017
Oncology experts from multiple countries collaborated on the SELECT-1 randomized clinical trial, which focused on treatment of KRAS-mutant advanced...
Oncology experts from multiple countries collaborated on the SELECT-1 randomized clinical trial, which focused on treatment of <I>KRAS</I>-mutant advanced non-small cell lung cancer (NSCLC).
MORE
May 11, 2017
May 11, 2017
FDA has approved expanding the use of pembrolizumab (Keytruda—Merck) to include adding it to chemotherapy to treat lung cancer. On Wednesday, FDA...
FDA has approved expanding the use of pembrolizumab (Keytruda&#8212;Merck) to include adding it to chemotherapy to treat lung cancer. On Wednesday, FDA approved combining pembrolizumab with two chemotherapy agents, pemetrexed and carboplatin, for the treatment of patients with an advanced form of lung cancer.
MORE
May 09, 2017
May 09, 2017
PTC Therapeutics said Monday that it would receive a net price of $35,000 annually per patient for deflazacort (Emflaza), the muscular dystrophy...
PTC Therapeutics said Monday that it would receive a net price of $35,000 annually per patient for deflazacort (Emflaza), the muscular dystrophy drug it acquired from Marathon Pharmaceuticals in April.
MORE
May 08, 2017
May 08, 2017
FDA has approved edaravone (Radicava—Mitsubishi Tanabe Pharma America) for the treatment of patients with amyotrophic lateral sclerosis (ALS), also...
FDA has approved edaravone (Radicava&#8212;Mitsubishi Tanabe Pharma America) for the treatment of patients with amyotrophic lateral sclerosis (ALS), also referred to as Lou Gehrig's disease.
MORE
May 04, 2017
May 04, 2017
The World Health Organization (WHO) announced plans to launch a pilot program for prequalifying biosimilar medications. Beginning this September,...
The World Health Organization (WHO) announced plans to launch a pilot program for prequalifying biosimilar medications.
MORE
May 04, 2017
May 04, 2017
Updated results for an ongoing study showcase the viability of treating hepatitis C virus (HCV) with imported, and thereby more affordable, generic...
Updated results for an ongoing study showcase the viability of treating hepatitis C virus (HCV) with imported, and thereby more affordable, generic versions of direct-acting antivirals.
MORE
April 28, 2017
April 28, 2017
A collaboration involving Walgreens and the American Society of Transplantation (AST) seeks to develop future initiatives to help improve medication...
A collaboration involving Walgreens and the American Society of Transplantation (AST) seeks to develop future initiatives to help improve medication adherence for organ transplant recipients.
MORE
April 28, 2017
April 28, 2017
FDA announced Thursday it has approved cerliponase alfa (Brineura—BioMarin Pharmaceutical) as a treatment for a particular form of Batten disease....
FDA announced Thursday it has approved cerliponase alfa (Brineura&#8212;BioMarin Pharmaceutical) as a treatment for a particular form of Batten disease.
MORE
April 28, 2017
April 28, 2017
FDA has expanded the approved use of regorafinib (Stivarga—Bayer HealthCare Pharmaceuticals) to include treatment of patients with hepatocellular...
FDA has expanded the approved use of regorafinib (Stivarga&#8212;Bayer HealthCare Pharmaceuticals) to include treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This is the first FDA-approved treatment for a liver cancer in nearly 10 years.
MORE
April 18, 2017
April 18, 2017
Clinicians have a better handle on prescribing erythropoiesis-stimulating agents (ESAs) appropriately for chemotherapy-related anemia and no longer...
Clinicians have a better handle on prescribing erythropoiesis-stimulating agents (ESAs) appropriately for chemotherapy-related anemia and no longer need special training to prescribe them, FDA announced. The ESAs in question are epoetin alfa (Epogen and Procrit&#8212;Amgen) and darbepoetin alfa (Aranesp&#8212;Amgen).
MORE

Pages